Developing a PD1-VEGFR2 Bifunctional Antibody and Advice for First-in-Class Value
Ottimo Pharma CEO David Epstein shares the potential benefits of a PD1-VEGFR2 bifunctional antibody, what drew him to the organization, and advice for understanding the value of first-in-class therapeutics.
Summary:
In this video interview, recorded in March 2025, Ottimo Pharma's CEO David Epstein describes the therapeutic value of developing a PD1-VEGFR antibody, what drew him to the biotech, and what his advice would be for R&D leaders on assessing value for first-in-class therapeutics. He also highlights lessons from his past roles at Seagen, Novartis and Flagship.